Myogen — Investor Presentation (July 2005)
34 slides from Myogen's investor presentation, Jul 12, 2005
Slide 1: Innovative therapies targeting cardiovascular disease
Innovative therapies Ss M targeting cardiovasculardisease Nasdaq: MYOG July 2005,
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the matters discussed in this presentation contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the completion and reporting of results from the Company's clinical trials. Actual results could differ
Slide 3: Myogen Highlights
Myogen Highlights Therapeutics for Cardiovascular Diseases Late-stage Product Pipeline Marketed product in Europe Two compounds / two indications / Phase 2b & 3 Commercial Rights Retained Integrated Target and Drug Discovery Platform Drug Discovery and Development Collaboration with Novartis
Slide 4: Myogen Product Portfolio
Myogen Product Portfolio Myogen Product Potential Indication Preclinical Phase1 Phase2 Phase3 Marketed Perfan® ILV. Acute Decompensated (.v.enoximone) Heart Failure Pulmonary Arterial Resistant Systolic Darusentan Hypertension Cardiac Hypertrophic Heart Failure Discovery Signaling
Slide 5: Myogen Product Portfolio
Myogen Product Portfolio Myogen Product Potential Indication Preclinical Phase1 Phase2 Phase3 Marketed Perfan® ILV. Acute Decompensated v.enoximone) Heart Failure Resistant Systolic ecaranamenanss > Darusentan Hypertension Cardiac Hypertrophic Heart Failure Discovery ignaling
Slide 6: Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) Severely debilitating, life-threatening disease Estimated 100,000 to 200,000 individuals w/w have PAH Multiple etiologies Primary pathogenesis is pulmonary endothelial cell dysfunction or injury leading to: Vasoconstriction Smooth-muscle cell and endothelial cel
Slide 7: Therapeutic Approaches
Therapeutic Approaches Vasodilator therapies Calcium channel blockers Endothelin receptor antagonists Prostacyclin analogues Nitric oxide donors Phosphodiesterase inhibitors Anti-coagulation and anti-platelet therapies Warfarin Prostacyclin analogues Phosphodiesterase inhibitors Anti-inflammatory th
Slide 8: Therapies
Therapies Calcium Channel Blockers Prostacyclin analogues Flolan (continuous i.v. epoprostenol) Remodulin (continuous s.q. or i.v. treprostinil) Ventavis (inhaled iloprost) Endothelin receptor antagonists Tracleer (oral bosentan b.i.d.) Phosphodiesterase inhibitors Revatio (oral sildenafil t.i.d) Co
Slide 9: Ambrisentan: ETA-selective second-generation ERA
Ambrisentan ETA-selective (260X) ETA receptor occupancy = 82-97% ETB receptor occupancy = 2-7% High potency and oral bioavailability Long half-life (9-15 hours) No significant p450 induction or inhibition No active metabolite - excreted in feces Linear pharmacokinetics Patent protection through 2015
Slide 10: Ambrisentan Potential Advantages
Ambrisentan Potential Advantages Efficacy Significant improvements in 6MWD, BDI, and WHO symptoms Durable efficacy with long term use (possible survival benefit) Comparable efficacy in Class II and Class III patients Selectivity for type-A receptor (pathological receptor) Dose flexibility (dose to m
Slide 11: Ambrisentan Clinical Program
Ambrisentan Clinical Program Phase 1 Phase 2 Phase 3 Healthy Volunteers Single Dose 63 subjects Healthy Volunteers Multiple Dose 30 subjects, 10 days AMB-220 Dose-Ranging 64 subjects, 12 wk Open-label Extension 12 wk Phase 2 Long-term AMB-220-E Phase 3 AMB-320 (ARIES-1) N. & S. America & Australia 1
Slide 12: Ambrisentan demonstrated significant efficacy
50 60 - -20 - -10 0 10 20 30 40 Change in 6MWD (meters) Bosentan BREATHE-1 n = 74 Sitaxsentan STRIDE I&II n= 55/62 placebo 100 mg 12 wks 18 wks 1-10 mg 12 wks 16 wks placebo 125 mg 16 wks Ambrisentan AMB-220 n= 64 Ambrisentan demonstrated significant efficacy 1- Rubin et al., Ambrisentan Improves Ex
Slide 13: Ambrisentan demonstrated significant efficacy
1 2 Ambrisentan demonstrated significant efficacy 1- Rubin et al., Ambrisentan Improves Exercise Capacity and Clinical Measures in PAH, 2004 Abstracts for the American Thoracic Society. 2- FDA Briefing Document on Tracleer for CardioRenal Advisory Panel, August 10, 2001 and Tracleer Product Labeling
Slide 14: Comparable efficacy in Class II and Class III patients
Baseline 6MWD: Class II=390 m; Class III=316 m 0 10 20 30 40 50 60 70 80 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Class II (n=23) Class III (n=41) Change in 6MWD (meters) Ambrisentan demonstrated comparable efficacy in patients with Class II and Class III symptoms
Slide 15: Significant improvements in disease symptoms
0 20 40 60 80 100 0 2 4 8 12 16 20 24 Class I Class II Class III Class IV n=64 n=62 n=62 n=58 n=58 n=55 n=54 n=54 Percent Week Ambrisentan demonstrated significant improvements in disease symptoms
Slide 16: Ambrisentan demonstrated durable efficacy
Week 0 Week 12 Week 24 Week 48 6MWD, n 64 64 64 64 6MWD, meters 343 379 397 397 Dyspnea, n 63 64 64 64 Dyspnea, Borg index 4.0 3.1 2.7 3.1 WHO Functional Class, n 64 64 64 64 Class I, % 0 11 12 11 Class II, % 36 48 47 48 Class III, % 64 41 41 41 Class IV, % 0 0 0 0 Ambrisentan demonstrated durable e
Slide 17: Ambrisentan demonstrated a survival benefit
50 60 70 80 90 100 100 200 300 Days Event-free patients (%) IPAH Patients, n = 39 92% Observed Survival vs 74% Predicted Survival Observed Survival Survival from NIH Registry Ambrisentan demonstrated a survival benefit
Slide 18: Well tolerated with low incidence of liver toxicity
0 5 10 15 20 25 30 LFTs >8X LFTs >3X Flushing Nausea Headache Nasal Congestion Upper Respiratory Tract Symptoms Peripheral Edema Percent of Patients with AE (%) Ambrisentan was well tolerated with low incidence of potential liver toxicity
Slide 19: Ambrisentan Phase 2 Results
Ambrisentan Phase 2 Results Efficacy Statistically significant and clinically meaningful increase in primary efficacy endpoint observed for all four doses Benefit seen in IPAH and SPAH and Class II and Class III patients Improvement in all secondary endpoints and pulmonary vascular hemodynamics Bene
Slide 20: Ambrisentan Clinical Program
Ambrisentan Clinical Program Phase 1 Phase 2 Phase 3 Healthy Volunteers Single Dose 63 subjects Healthy Volunteers Multiple Dose 30 subjects, 10 days AMB-220 Dose-Ranging 64 subjects, 12 wk Open-label Extension 12 wk Phase 2 Long-term AMB-220-E Phase 3 AMB-320 (ARIES-1) N. & S. America & Australia 1
Slide 21: Ambrisentan Potential Advantages
Ambrisentan Potential Advantages Efficacy Significant improvements in 6MWD, BDI, and WHO symptoms Durable efficacy with long term use (possible survival benefit) Comparable efficacy in Class II and Class III patients Selectivity for type-A receptor (pathological receptor) Dose flexibility (dose to m
Slide 22: Ambrisentan has potential to become ERA of choice
Ambrisentan has potential to become ERA of choice Vasodilator therapies Calcium channel blockers Endothelin receptor antagonists Prostacyclin analogues Nitric oxide donors Phosphodiesterase inhibitors Anti-coagulation and anti-platelet therapies Warfarin Prostacyclin analogues Phosphodiesterase inhi
Slide 23: PAH may be the first of several pulmonary disorders that respond to ERAs
PAH may be the first of several pulmonary disorders that respond to ERAs WHO CLASSIFICATION OF PULMONARY HYPERTENSION Pulmonary arterial hypertension Idiopathic Familial Associated with Collagen vascular disease Congenital left-to-right shunt Portal hypertension Infection with HIV Drugs and toxins P
Slide 24: Myogen Product Portfolio
Myogen Product Portfolio Myogen Product Potential Indication Precii Acute Decompensated Heart Failure Pulmonary Arterial Hypertension ‘al Phase1 Phase2 Phase3 Marketed Ambrisentan Cardiac Hypertrophic Heart Failure Discovery Signaling
Slide 25: Darusentan Characteristics
Darusentan Characteristics ETA-selective Long half-life (16-18 hours...potential once daily dosing) Not metabolized through p450 system - no drug-drug interactions observed Approximately 1,500 patients studied in Phase 2/3 Potent anti-hypertension properties Well tolerated No evidence of liver toxic
Slide 26: Darusentan demonstrated potent anti-hypertensive properties
Randomized, double-blinded, placebo controlled Phase II/III 390 patients with moderate hypertension Europe and Israel, 56 sites HEAT Investigators, American Journal of Hypertension, 2002, v25, pp. 583-589 Darusentan demonstrated potent anti- hypertensive properties as monotherapy
Slide 27: Resistant Systolic Hypertension
Resistant Systolic Hypertension 100 million individuals in US & EU have hypertension Despite use of multiple drug classes many remain hypertensive leading to cardiovascular events The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pres
Slide 28: Prevalence of Resistant Hypertension
Prevalence of Resistant Hypertension "Using the definition of concomitant prescription of three or more antihypertensive medications, recent clinical trials indicate that resistant hypertension is common, affecting 20% to 30% of the different study populations." (S. Oparil and M.A. Weber, HYPERTENSI
Slide 29: Darusentan Phase 2b study design
10 mg 50 mg 100 mg 150 mg 300 mg Study Week - -2 0 4 6 Randomization Placebo Treatment Period - -4 Screening Period Placebo Run-in Withdrawal 10 8 2 100 mg 11 12 Final Safety Visit P P 115 patients randomized 1:2 Darusentan Phase 2b Enrollment completed in April; results expected in August
Slide 30: Darusentan Potential
Darusentan Potential Clear guidance from FDA on what is required for registration First ERA approved for hypertension (major new class) No drug-drug interactions (combination therapy) Once-a-day dosing Dosing flexibility Long patent life (2015) Darusentan could be the first of a new class of agents
Slide 31: Integrated Target & Drug Discovery Platform
Integrated Target & Drug Discovery Platform Intact human heart gene expression Human cardiomyocyte culture Molecular Targets for Heart Failure High Throughput Assays for Screening & Drug Discovery Validation Cardiac signaling pathways Cardiogenomics Cardioproteomics Fetal Gene Program Heart Tissue B
Slide 32: Drug Discovery and Development Partnership with Novartis
Drug Discovery and Development Partnership with Novartis Broad strategic partnership in heart muscle disease Expanded in 2Q 2005 to include HDAC inhibitor program Annual research funding to Myogen for 3 years, annually renewable thereafter Significant commitment of Novartis resources Success milesto
Slide 33: Selected Financial Information
Selected Financial Information
Slide 34: 2005 Guidance
2005 Guidance (as of June 27, 2005)1 Complete ARIES-2 enrollment July Darusentan Phase 2b results By end of August Complete ARIES-1 enrollment Q4 ARIES-2 results Year-end 1- The guidance was effective on the date it was issued and it is our policy not to publicly or privately confirm prior guidance